
    
      This protocol is designed to use stereotactic body radiation therapy (SBRT) to deliver a
      boost dose to residual primary tumor after definitive doses of standard external beam
      radiation have been delivered concurrently with chemotherapy. It is designed to determine the
      toxicity profile(side effects) in the context of dose escalation of stereotactic body
      radiation therapy (SBRT) after definitive therapy with concurrent chemoradiation and to
      define the maximum tolerated dose.

      Serum levels of TGF-Beta1 have been demonstrated to correlate with the incidence of the
      radiation toxicity, pneumonitis in patients treated with standard external beam radiation.
      This study will serially follow TGF-Beta1 levels in patients to see if the same correlation
      exists with SBRT toxicity.
    
  